Nasdaq · Common Stock · Biological Products, (No Diagnostic Substances)
17 entities across 3 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-02-23 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Infacell Therapeutics, Inc. | Delaware | |
| ImmunityBio Ireland Ltd. | Ireland | |
| NantCell, Inc. | Delaware | |
| Etubics Corporation | Delaware | |
| Altor BioScience, LLC | Delaware | |
| Altor BioScience Manufacturing Company LLC | Delaware | |
| Receptome, Inc. | Delaware | |
| VBC Holdings LLC | Delaware | |
| VivaBioCell, S.p.A. | Italy | |
| GlobeImmune, Inc. | Delaware | |
| Immunotherapy NANTibody, LLC | Delaware | |
| IgDraSol, Inc. | Delaware | |
| MCLR Parent LLC | Delaware | |
| Mariposa Clinic Co LLC | Delaware | |
| Mariposa Lab Co LLC | Delaware | |
| Mariposa Radiology Co LLC | Delaware | |
| AccessBio LLC | Delaware |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $605,000 | −$92.4M | −$73.1M | — | 377,067,527 |
| FY2021 | $934,000 | −$346.8M | −$308.0M | — | 389,234,156 |
| FY2022 | $240,000 | −$416.6M | −$415.7M | — | 399,900,374 |
| FY2023 | $622,000 | −$583.2M | −$397.3M | — | 508,635,592 |
| FY2024 | $14.7M | −$413.6M | −$398.1M | — | 700,443,000 |
| FY2025 | $113.3M | −$351.4M | −$308.8M | — | 919,863,000 |
13 institutions tracked — 6 added, 6 reduced, 1 opened a new position. Index money added 13,243,129 shares while active managers cut 104,861.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| BlackRock, Inc. | Index | 34,083,262 | +7,736,819 | $298.4M |
| STATE STREET CORP | Index | 21,398,438 | +3,690,335 | $187.3M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 9,847,896 | +1,815,975 | $86.2M |
| MORGAN STANLEY | Active fund | 3,432,678 | −586,191 | $30.1M |
| CITADEL ADVISORS LLC | Hedge fund | 5,674,645 | +538,767 | $49.7M |
| BANK OF AMERICA CORP /DE/ | Active fund | 2,184,489 | −263,354 | $19.1M |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 222,862 | +156,315 | $2.0M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 441,444 | +146,613 | $3.9M |
| JPMORGAN CHASE & CO | Active fund | 1,450,180 | −44,529 | $12.9M |
| Point72 Asset Management, L.P. | Hedge fund | 132,000 | −28,100 | $1.2M |
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 110,684 | −23,171 | $969,039 |
| FMR LLC | Active fund | 29,493 | −1,211 | $258,211 |
RENAISSANCE TECHNOLOGIES LLC holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
ImmunityBio, Inc. files under SIC 2836 — all 11 biological products, (no diagnostic substances) companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
